NO960380L - Middel til behandling av neurosykdommer - Google Patents

Middel til behandling av neurosykdommer

Info

Publication number
NO960380L
NO960380L NO960380A NO960380A NO960380L NO 960380 L NO960380 L NO 960380L NO 960380 A NO960380 A NO 960380A NO 960380 A NO960380 A NO 960380A NO 960380 L NO960380 L NO 960380L
Authority
NO
Norway
Prior art keywords
peripheral
treatment
alkyl
neurological diseases
nervous
Prior art date
Application number
NO960380A
Other languages
English (en)
Other versions
NO960380D0 (no
Inventor
Jin-Ichi Inokuchi
Yoichiro Kurado
Kazuyo Muramoto
Haruki Yamada
Seigou Usuki
Original Assignee
Seikagaku Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Kogyo Co Ltd filed Critical Seikagaku Kogyo Co Ltd
Publication of NO960380D0 publication Critical patent/NO960380D0/no
Publication of NO960380L publication Critical patent/NO960380L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings

Abstract

Det bekjentgjøres et middel for helbredelse av nevronale sykdommer som forårsakes av forstyrrelser av det perifere nervesytem eller sentralnervesystemet. Middelet omfatter et at 2-acylaminopropanol derivat som har formelen (I): R1-CH-CH-CH2¿N O OH NHCO(CH2)nCH3 (D [hvor i R er en fenylgruppe eller syklohexylgruppe som hver for seg kan være substituert med l til 3 like eller forskjellige substituenter som utvelges fra den gruppe som består av alkyl, alkoxy, hydroksy og nitro, eller er en alkylgruppe, og n er et heltall på O til 16] eller et farmasøytisk akseptabelt salt derav som virksom bestandel. Det akselererer nevroittforlengelse og synapsedannelse ved å øke biosyntese av nevrosytters endogene sfingoglykolipid, særskilt gangliosid, hvor ved det kan benyttes for helbredelse av forskjellige sykdommer i sentral nervesystemet og det ; perifere nervesystem.
NO960380A 1993-08-13 1996-01-30 Middel til behandling av neurosykdommer NO960380L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22051893 1993-08-13
PCT/JP1994/001342 WO1995005177A1 (fr) 1993-08-13 1994-08-12 Remede contre les maladies nerveuses

Publications (2)

Publication Number Publication Date
NO960380D0 NO960380D0 (no) 1996-01-30
NO960380L true NO960380L (no) 1996-03-14

Family

ID=16752277

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960380A NO960380L (no) 1993-08-13 1996-01-30 Middel til behandling av neurosykdommer

Country Status (12)

Country Link
US (2) US5707649A (no)
EP (1) EP0720852B1 (no)
JP (1) JP3778926B2 (no)
KR (1) KR960703598A (no)
CN (1) CN1128951A (no)
AT (1) ATE197672T1 (no)
AU (1) AU676361B2 (no)
DE (1) DE69426331T2 (no)
HU (1) HUT73527A (no)
NO (1) NO960380L (no)
NZ (1) NZ269847A (no)
WO (1) WO1995005177A1 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT73527A (en) * 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
NO965193L (no) * 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
US5972928A (en) * 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
US6440455B1 (en) * 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
US6723838B1 (en) 1998-04-22 2004-04-20 Johns Hopkins University Signal transducing synaptic molecules and uses thereof
DE69939651D1 (de) 1998-06-29 2008-11-13 Los Angeles Childrens Hospital Behandlung hyperproliferativer erkrankungen
US6368831B1 (en) 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
AU756008B2 (en) * 1998-07-27 2003-01-02 Johns Hopkins University, The Methods for treating conditions modulated by lactosylceramide
US6635281B2 (en) * 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
EP1384719A1 (en) * 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections
US6407064B2 (en) 1999-12-06 2002-06-18 Seikagaku Corporation Aminoalcohol derivative and medicament comprising the same
JP5009459B2 (ja) * 1999-12-06 2012-08-22 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
US20100261159A1 (en) 2000-10-10 2010-10-14 Robert Hess Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
BR0206400A (pt) * 2001-01-10 2005-01-18 Univ Michigan Compostos de amino ceramidas e seus usos em métodos terapêuticos
JP3742602B2 (ja) * 2001-05-09 2006-02-08 株式会社カネカ 還元型補酵素ｑの安定な溶液
PT2266968E (pt) * 2001-07-16 2013-02-25 Genzyme Corp Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
DE10352450A1 (de) * 2003-11-07 2005-06-23 Ruprecht-Karls-Universität Heidelberg Neues Mittel zur prophylaktischen und/oder therapeutischen Behandlung von Morbus Alzheimer
DE10352449A1 (de) * 2003-11-07 2005-06-16 Ruprecht-Karls-Universität Heidelberg Mittel zur prophylaktischen und/oder therapeutischen Behandlung von Morbus Alzheimer
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
US20090111812A1 (en) * 2004-06-14 2009-04-30 Musc Foundation For Research Development Methods for treating inflammatory disorders
BRPI0517701A8 (pt) * 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
CN101151248B (zh) * 2005-01-26 2012-06-20 阿勒根公司 具有镇痛活性和/或免疫刺激物活性的3-芳基-3-羟基-2-氨基丙酸酰胺类、3-杂芳基-3-羟基-2-氨基丙酸酰胺类以及相关化合物
EP1857112B1 (en) * 2005-03-09 2013-05-15 Sunstar Inc. Anticancer composition comprising liposomes containing phytosterols
CA2650691C (en) * 2006-04-28 2015-10-06 Children's Hospital Medical Center Fusogenic properties of saposin c and related proteins and peptides for application to transmembrane drug delivery systems
ES2546181T3 (es) * 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
WO2008011487A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
WO2008011483A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
US20100190792A1 (en) * 2007-03-06 2010-07-29 Allergan, Inc Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008150486A2 (en) 2007-05-31 2008-12-11 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
WO2009045503A1 (en) 2007-10-05 2009-04-09 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US8389517B2 (en) 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP2349255B1 (en) 2008-10-03 2016-03-30 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
JPWO2010087313A1 (ja) * 2009-01-29 2012-08-02 株式会社林原生物化学研究所 神経突起伸展促進剤
CA2817198C (en) * 2009-11-12 2018-05-01 Texas Tech University Compositions and methods for treating hyperproliferative disorders
AU2010324810B2 (en) 2009-11-27 2016-05-12 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
US9134315B2 (en) 2010-02-12 2015-09-15 The Johns Hopkins University Use of the lactosylceramide synthase isoform B1,4GalT-V as a biomarker for cancer
WO2016126572A2 (en) 2015-02-02 2016-08-11 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
EP3501495A1 (en) * 2017-12-21 2019-06-26 InnoMedica Holding AG Liposomes comprising sphingomyelin
JP2022553107A (ja) 2019-10-23 2022-12-21 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン グルコシルセラミドシンターゼ阻害剤およびそれを使用する治療方法
US20230212123A1 (en) 2020-04-28 2023-07-06 The Regents Of The University Of Michigan Pyridine Inhibitors of Glucosylceramide Synthase and Therapeutic Methods Using the Same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963297A (en) * 1987-12-22 1990-10-16 The Liposome Company, Inc. Spontaneous vesticulation of multilamellar liposomes
US5041441A (en) * 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
HUT73527A (en) * 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases

Also Published As

Publication number Publication date
HUT73527A (en) 1996-08-28
AU676361B2 (en) 1997-03-06
CN1128951A (zh) 1996-08-14
DE69426331D1 (de) 2000-12-28
US5707649A (en) 1998-01-13
AU7350694A (en) 1995-03-14
KR960703598A (ko) 1996-08-31
HU9600278D0 (en) 1996-04-29
WO1995005177A1 (fr) 1995-02-23
NO960380D0 (no) 1996-01-30
JP3778926B2 (ja) 2006-05-24
NZ269847A (en) 1996-11-26
DE69426331T2 (de) 2001-06-21
EP0720852B1 (en) 2000-11-22
US5849326A (en) 1998-12-15
EP0720852A4 (en) 1997-07-23
EP0720852A1 (en) 1996-07-10
ATE197672T1 (de) 2000-12-15

Similar Documents

Publication Publication Date Title
NO960380L (no) Middel til behandling av neurosykdommer
FI935529A (fi) Aminometylensubstituerade icke-aromatiska heterocykliska foereningar
HU9603433D0 (en) Novel 4-6-diaryl-pyrimidine-derivatives and salts thereof
DE3263734D1 (en) Derivatives of 1-aryl-2-aminomethyl-cyclopropane-carboxamides (z), their preparation and their use as medicines in the treatment of disorders of the central nervous system
RU2203274C2 (ru) Спироциклические ингибиторы металлопротеаз
ES2106573T3 (es) Composicion oftalmica que contiene un derivado de 1,5-benzoxatiepina para tratar glaucoma.
DE68914292T2 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
DE69326395T2 (de) Spirooxathiolan-quinuclidin-Derivat zur Behandlung des Sjögren-Syndroms
DE69008142D1 (de) 4-Substituierten Imidazolen zur Senkung des intraokularen Druckes.
NO943895L (no) Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter
NO944915D0 (no) Öking av trambomodulinekspresjon
ATE284684T1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
HUT72441A (en) Pharmaceutical compositions comprising bicycloheptane derivative and process for producing them
KR880007495A (ko) 5-아릴-3h-1,2,4-트리아졸-3-온 및 신경변성 질환의 치료에 있어서의 그들의 용도
DK0551844T3 (da) Svovlholdige galdesyrederivater
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems
ES2168119T3 (es) Derivados de quinoxalina para el tratamiento de tinnitus.
DE69401521D1 (de) Piperidin-Derivate mit antihistaminischer und antileukomenischer Wirkung
RU96105023A (ru) Агент для лечения нейрональных заболеваний